340023-04-3 Usage
Molecular Structure
1-ethenyl-2-oxabicyclo[2.2.2]octane-4-carboxylic acid has a complex molecular structure, featuring a bicyclic ring system with an ethenyl group attached to one of the carbon atoms.
Carboxylic Acid Derivative
This compound is a derivative of carboxylic acid, which means it contains a carboxyl functional group (-COOH) attached to a carbon chain.
Bicyclic Ring System
The compound features a unique bicyclic ring system, which consists of two fused rings within the molecule. In this case, the bicyclic system is formed by an eight-membered ring and a three-membered ring.
Ethenyl Group
The presence of an ethenyl group (a vinyl group with a double bond) in the structure contributes to the compound's unique properties and potential applications.
Potential Applications
Due to its unique structure and functional groups, 1-ethenyl-2-oxabicyclo[2.2.2]octane-4-carboxylic acid may have potential uses in various fields, such as pharmaceuticals, materials science, and other industries.
Further Research
To fully understand the properties and potential applications of this compound, additional research and experimentation may be necessary. This includes studying its chemical reactivity, stability, and interactions with other compounds or materials.
Check Digit Verification of cas no
The CAS Registry Mumber 340023-04-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,4,0,0,2 and 3 respectively; the second part has 2 digits, 0 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 340023-04:
(8*3)+(7*4)+(6*0)+(5*0)+(4*2)+(3*3)+(2*0)+(1*4)=73
73 % 10 = 3
So 340023-04-3 is a valid CAS Registry Number.
340023-04-3Relevant articles and documents
Oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad spectrum antibacterial agents
Singh, Sheo B.,Kaelin, David E.,Wu, Jin,Miesel, Lynn,Tan, Christopher M.,Meinke, Peter T.,Olsen, David,Lagrutta, Armando,Bradley, Prudence,Lu, Jun,Patel, Sangita,Rickert, Keith W.,Smith, Robert F.,Soisson, Stephen,Wei, Changqing,Fukuda, Hideyuki,Kishii, Ryuta,Takei, Masaya,Fukuda, Yasumichi
, p. 609 - 614 (2014)
Bacterial resistance is eroding the clinical utility of existing antibiotics necessitating the discovery of new agents. Bacterial type II topoisomerase is a clinically validated, highly effective, and proven drug target. This target is amenable to inhibit
BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS
-
, (2013/03/26)
Novel bridged bicyclic compounds are disclosed herein, along with their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antibacterial agents. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating bacterial infections and associated diseases and conditions.
